Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment
Antimycobacterial Susceptibility Testing Group, Sophia B. Georghiou, Timothy C. Rodwell, Alexei Korobitsyn, Said Abbadi, Kanchan Ajbani, Jan‐Willem C. Alffenaar, David Alland, N. Alvarez, Sönke Andres, Elisa Ardizzoni, Alexandra Aubry, Rossella Baldan, Marie Ballif, Ivan Barilar, Erik C. Böttger, Soumitesh Chakravorty, Pauline Claxton, Daniela María Cirillo, Iñaki Comas, Chris Coulter, Claudia M. Denkinger, Brigitta Derendinger, Edward Desmond, Jurriaan E.M. de Steenwinkel, Keertan Dheda, Andreas H. Diacon, David L. Dolinger, Kelly E. Dooley, Matthias Egger, Soudeh Ehsani, Maha Farhat, Lanfranco Fattorini, Iris Finci, Laure Fournier Le Ray, Victoria Furió, Ramona Groenheit, Tawanda Gumbo, Scott K. Heysell, Doris Hillemann, Harald Hoffmann, Po‐Ren Hsueh, Yi Hu, Hairong Huang, Azhar Hussain, Farzana Ismail, Kiyohiko Izumi, Tomasz Jagielski, John L. Johnson, Priti Kambli, Koné Kaniga, G.H.R. Eranga Karunaratne, Meenu K. Sharma, Peter M. Keller, Ellis Kelly, Margarita S. Kholina, Mikashmi Kohli, Katharina Kranzer, Ian F. Laurenson, Jason Limberis, S-Y G Lin, Yongge Liu, Alexandre López-Gavín, Anna Lyander, Diana Machado, Elena Martínez, Faisal Masood, Satoshi Mitarai, Nomonde R. Mvelase, Stefan Niemann, Vladyslav Nikolayevskyy, Florian P. Maurer, Matthias Merker, Paolo Miotto, Shaheed Vally Omar, Ralf Otto-Knapp, Moisés Palaci, Juan J. Palacios, Sharon J. Peacock, Charles A. Peloquin, Jennifer Perera, Catherine Pierre-Audigier, Suporn Pholwat, James E. Posey, Therdsak Prammananan, Leen Rigouts, Jaime Robledo, Neesha Rockwood, Camilla Rodrigues, Max Salfinger, Marcos C. Schechter, Marva Seifert, Sarah Sengstake, Thomas Shinnick, Natalia Shubladze, Vitali Sintchenko, Frederick A. Sirgel, S. Somasundaram, Timothy R. Sterling, Andrea Spitaleri
Abstract
Inappropriately high breakpoints have resulted in systematic false-susceptible AST results to anti-TB drugs. MIC, PK/PD and clinical outcome data should be combined when setting breakpoints to minimise the emergence and spread of antimicrobial resistance.